Amwell Posts $11.4M Q3 Loss as Top-Line Pressure Persists
AMWL has more than doubled off its 52-week low of $3.71.
Summary
Amwell reported a $11.4M loss for the third quarter, a loss of 67 cents per share. That is wider than the $9.6M net loss it posted in Q2, when revenue fell 27% to $52M despite deep cost cuts and positive operating cash flow. The company had raised full-year 2026 revenue guidance to $200-$205M in August and narrowed its adjusted EBITDA loss forecast, and it has again raised its 2026 revenue and adjusted EBITDA outlook. Third-quarter revenue beat estimates on subscriptions and AMG, so the top-line trend versus the $52M Q2 base is no longer the key unknown. Cash stood at $195.9M at the last report, and the burn implied by this loss keeps runway in focus for a company this size.
At the time of this announcement, AMWL was trading at $12.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $216.7M. The 52-week trading range was $3.71 to $15.16. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.